Biotech | January 03, 2022
Ascletis expands ritonavir oral tablet production
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
The QuickVue antigen tests are able to detect the live Omicron variant with similar performance as with other variants
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
The product is expected to be available in a week’s time
DCGI approved the drug based on the review of clinical data
The drug will be marketed under the brand name Molnaflu
This product will be manufactured at Lupin's Goa facility in India
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
Subscribe To Our Newsletter & Stay Updated
